Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 StudyAndy Itsara, Adrian Wiestner, Susan Soto et al.|Blood|2023Cited by 10
A decade of ibrutinib for CLL with and without <i>TP53</i> aberration: final report on an investigator-sponsored phase 2 studyAndy Itsara, Adrian Wiestner, Victoria Rogness et al.|Blood|2025Cited by 3